XBiotech (XBIT) Other Non-Current Liabilities (2019 - 2026)

XBiotech has reported Other Non-Current Liabilities for 8 years, with the latest figure at $1.8 million in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 4.03% year-over-year to $1.8 million in Q2 2026; TTM through Jun 2026 was $1.8 million, a 4.03% increase from a year earlier, with the FY2025 full-year figure at $1.8 million, up 4.53% from the prior year.
• Other Non-Current Liabilities was $1.8 million for Q2 2026 at XBiotech, up from $1.8 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $1.8 million in Q2 2026, with the low at $1.5 million in Q1 2022.
• Average Other Non-Current Liabilities over 5 years is $1.7 million, with a median of $1.7 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities surged 31.94% in 2022, then gained 2.01% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $1.6 million in 2022, then increased by 5.9% to $1.7 million in 2023, then gained by 3.06% to $1.7 million in 2024, then advanced by 4.53% to $1.8 million in 2025, then grew by 1.89% to $1.8 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.8 million (Q2 2026), $1.8 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.